Ohio

Psychedelic trials in Ohio

39 registered trials has a study site in Ohio, and 6 are recruiting now.

Trials with a site here

Recruiting

Facilities

Open now

Recruiting in this state

Trial	Status	Phase	Substance	Sites
A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend)NCT07592689 · Definium Therapeutics US, Inc.	Recruiting	Phase 3	lsd	30
A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive DisorderNCT07227454 · Janssen Research & Development, LLC	Recruiting	Phase 3	ketamine	35
Ketamine Treatment of Youth Suicide AttemptersNCT04763343 · Tatiana Falcone, MD	Recruiting	Phase 3	ketamine	1
A Mechanistic Study to Assess a Single Dose of CYB003 in Participants With Depression and AnxietyNCT06820723 · Ohio State University	Recruiting	Phase 2	psilocybin	1
Mindfulness-based Psilocybin Therapy for PTSDNCT07104916 · Anthony P King	Recruiting	Phase 2	psilocybin	1
Psilocybin-Assisted Therapy for the Treatment of Major Depressive Disorder in Patients With Non-Small Cell Lung CancerNCT07216404 · Alan Davis	Recruiting	Phase 2	psilocybin	1

Facilities

Where the research happens in Ohio

Facility	City	Trials
Cleveland Clinic	Cleveland	3
University of Cincinnati	Cincinnati	3
Cleveland Clinic Lutheran Hospital	Cleveland	3
Ohio State University	Columbus	2
Midwest Clinical Research Center	Dayton	2
The Ohio State University	Columbus	2
Neuro-Behavioral Clinical Research	Canton	2
University of Cincinnati, Dept of Psychiatry & Behavioral Neuroscience	Cincinnati	2
Seelos Investigational Site	Cincinnati	2
The Cleveland Clinic	Cleveland	1
The Ohio State University Department of Psychiatry	Columbus	1
The Ohio State University Medical Center	Columbus	1
Ohio State University Comprehensive Cancer Center	Columbus	1
Harding Hospital	Columbus	1
Cincinnati VA Medical Center, Cincinnati, OH	Cincinnati	1
Louis Stokes VA Medical Center, Cleveland, OH	Cleveland	1
University of Cincinnati Medical Center	Cincinnati	1
Neurobehavioral Clinical Research	North Canton	1
Insight Clinical Trials, LLC	Beachwood	1
Neuro-Behaviroral Clinical Research, Inc.	North Canton	1
University of Cincinnati, Department of Psychiatry & Behavirol Neuroscience	Cincinnati	1
Cleveland Clinic - Lutheran Hospital	Cleveland	1
University of Cincinnati Psychiatry- Anxiety Disorders Research Program	Cincinnati	1
Neuro-Behavioral Clinical Research, Inc.	North Canton	1
Nationwide Children's Hospital	Columbus	1
Clinical Site 103	Beachwood	1
Clinical Site 119	North Canton	1
Ohio State University Department of Psychiatry and Behavioral Health at the Davis Medical Research Center	Columbus	1
Lutheran Hospital - Cleveland Clinic	Cleveland	1
The Ohio State University, Department of Psychiatry & Behavioral Health	Columbus	1
Clinical Site 138	Middleburg Heights	1
Clinical Site 127	North Canton	1
University of Cincinnati Hospital	Cincinnati	1
University Hospital of Cleveland	Cleveland	1
Clinical Research Site	Dayton	1
Cleveland Clinic Foundation Center for Behavioral Health	Cleveland	1

Stay told

When a trial opens in Ohio

All trials

Every trial with a Ohio site

Trial	Status	Phase	Substance	Sites
A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend)NCT07592689 · Definium Therapeutics US, Inc.	Recruiting	Phase 3	lsd	30
A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive DisorderNCT07227454 · Janssen Research & Development, LLC	Recruiting	Phase 3	ketamine	35
Ketamine Treatment of Youth Suicide AttemptersNCT04763343 · Tatiana Falcone, MD	Recruiting	Phase 3	ketamine	1
A Mechanistic Study to Assess a Single Dose of CYB003 in Participants With Depression and AnxietyNCT06820723 · Ohio State University	Recruiting	Phase 2	psilocybin	1
Mindfulness-based Psilocybin Therapy for PTSDNCT07104916 · Anthony P King	Recruiting	Phase 2	psilocybin	1
Psilocybin-Assisted Therapy for the Treatment of Major Depressive Disorder in Patients With Non-Small Cell Lung CancerNCT07216404 · Alan Davis	Recruiting	Phase 2	psilocybin	1
Comparative Effectiveness of ECT vs. KETAMINE Over the LifespanNCT06034821 · Brigham and Women's Hospital	Enrolling by invitation	Phase 4	ketamine	10
Ketamine-Assisted Mindfulness-Based Cognitive Therapy for Depression: A Pilot StudyNCT05950711 · Ohio State University	Active, not recruiting	Phase 4	ketamine	1
A Study of Esketamine Nasal Spray, Administered as Monotherapy, in Adult Participants With Treatment-resistant DepressionNCT04599855 · Janssen Research & Development, LLC	Completed	Phase 4	ketamine	54
VA Aripiprazole vs Esketamine for Treatment Resistant DepressionNCT05554627 · VA Office of Research and Development	Withdrawn	Phase 4	ketamine	26
The BIO-K Study: A Single-Arm, Open-Label, Biomarker Development Clinical Trial of Ketamine for Non-Psychotic Unipolar Major Depression and Bipolar I or II Depression.NCT03156504 · Mayo Clinic	Completed	Phase 4	ketamine	4
"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder"NCT06564818 · Cybin IRL Limited	Active, not recruiting	Phase 3	psilocybin	45
Efficacy, Safety, and Tolerability of COMP360 in Participants With TRDNCT05624268 · COMPASS Pathways	Completed	Phase 3	psilocybin	40
Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRDNCT05711940 · COMPASS Pathways	Active, not recruiting	Phase 3	psilocybin	116
A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Panorama)NCT06809595 · Definium Therapeutics US, Inc.	Active, not recruiting	Phase 3	lsd	36
A Phase 3 Trial of DT120 for Major Depressive Disorder (Emerge)NCT06941844 · Definium Therapeutics US, Inc.	Active, not recruiting	Phase 3	lsd	22
A Phase 3 Trial of DT120 for Generalized Anxiety Disorder (Voyage)NCT06741228 · Definium Therapeutics US, Inc.	Active, not recruiting	Phase 3	lsd	34
A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant DepressionNCT02417064 · Janssen Research & Development, LLC	Completed	Phase 3	ketamine	90
A Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Participants With Treatment-resistant DepressionNCT02422186 · Janssen Research & Development, LLC	Completed	Phase 3	ketamine	69
A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant DepressionNCT02497287 · Janssen Research & Development, LLC	Completed	Phase 3	ketamine	109
A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant DepressionNCT02782104 · Janssen Research & Development, LLC	Completed	Phase 3	ketamine	173
54135419SUI3001: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Adult Participants Assessed to be at Imminent Risk for SuicideNCT03039192 · Janssen Research & Development, LLC	Completed	Phase 3	ketamine	56
54135419SUI3002: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Adult Participants Assessed to be at Imminent Risk for SuicideNCT03097133 · Janssen Research & Development, LLC	Completed	Phase 3	ketamine	61
ELEKT-D: Electroconvulsive Therapy (ECT) vs. Ketamine in Patients With Treatment Resistant Depression (TRD)NCT03113968 · Bo Hu	Completed	Phase 2 / Phase 3	ketamine	5
Emergency Ketamine Treatment of Suicidal IdeationNCT02183272 · University of Cincinnati	Unknown status	Phase 2 / Phase 3	ketamine	1
An Open Prospective Trial of IV Ketamine in Suicidal AdolescentsNCT02048423 · Nationwide Children's Hospital	Unknown status	Phase 2 / Phase 3	ketamine	1
A Study of CLE-100 (Oral Esketamine) as an Adjunctive Treatment to Standard Antidepressants for Major Depressive DisorderNCT06340958 · Clexio Biosciences Ltd.	Completed	Phase 2	ketamine	23
Psilocybin for the Treatment of Veterans With Post-Traumatic Stress DisorderNCT05554094 · Ohio State University	Active, not recruiting	Phase 2	psilocybin	1
A Dose-Finding Study of MM120 (LSD D-Tartrate) for the Treatment of Anxiety SymptomsNCT05407064 · Definium Therapeutics US, Inc.	Completed	Phase 2	lsd	22
Repeated Neurocognitive Measurements in Depressed PatientsNCT05991232 · Jay Fournier	Withdrawn	Phase 1 / Phase 2	ketamine	1
FMRI of Patients Receiving IV Ketamine for Treatment Resistant Bipolar DepressionNCT06620042 · Brian Barnett	Completed	Phase 2	ketamine	2
A Study of CLE-100 (Oral Esketamine) in Addition to Standard Antidepressant Drug for Major Depressive Disorder - CLEO StudyNCT04103892 · Clexio Biosciences Ltd.	Completed	Phase 2	ketamine	46
A Double-blind Study to Assess the Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Participants Who Are Assessed to be at Imminent Risk for SuicideNCT02133001 · Janssen Research & Development, LLC	Completed	Phase 2	ketamine	14
Study to Evaluate the Efficacy and Safety of 3 Fixed Doses of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Pediatric Participants Assessed to be at Imminent Risk for SuicideNCT03185819 · Janssen Research & Development, LLC	Completed	Phase 2	ketamine	51
A Randomized, Placebo-Controlled, Double-Blind Study to Assess Safety and Efficacy of PCN-101 in TRDNCT05414422 · Perception Neuroscience	Completed	Phase 2	ketamine	21
A Study of SLS-002 (Intranasal Racemic Ketamine) in Adults With Major Depressive Disorder at Imminent Risk of SuicideNCT04669665 · Seelos Therapeutics, Inc.	Completed	Phase 2	ketamine	21
A Study to Assess Feasibility of Using Clinician-directed and Digital Application Supported Cognitive Behavior Therapy (CBT) in Conjunction With Esketamine in Participants With Treatment-resistant DepressionNCT05268497 · Janssen Research & Development, LLC	Withdrawn	Phase 1	ketamine	5
Ketamine for Major Depressive DisorderNCT03721900 · Shenox Pharmaceuticals, LLC	Unknown status	Phase 1	ketamine	3
Administration of Subanesthetic Dose of Ketamine and Electroconvulsive Treatment for Treatment Resistant DepressionNCT02522377 · The Cleveland Clinic	Completed	Not applicable	ketamine	1

Site locations from ClinicalTrials.gov API v2, data build 2026-08-25.

Elsewhere